Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817004) titled 'QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration' on Sept. 2.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Prevention. Masking: None (Open Label).

Primary Sponsor: Qilu Pharmaceutical (Hainan) Co., Ltd.

Condition: Chemotherapy-Induced Nausea and Vomiting (CINV)

Intervention: Drug: apripitant and palonosetron injectable emulsion Drug: palonosetron hydrochloride injection

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 2026

Target Sample Size: 42

To know ...